Results 71 to 80 of about 321,312 (283)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS

HemaSphere, 2022
R. Steiner, P. Strati, C. Flowers, S. Neelapu, M. Green, L. Nastoupil, F. Hagemeister, L. Feng, S. Ahmed, R. Nair, L. Fayad, H. Lee, M. A. Rodriguez, J. Westin   +13 more
doaj   +1 more source

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma [PDF]

, 2016
Hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for hematologic malignancies and has shown modest activity in solid tumors, including ...
Bogaerts, Eliene, Coucke, Céline, Devisscher, Lindsey, Geerts, Anja, Laukens, Debby, Libbrecht, Louis, Paridaens, Annelies, Raevens, Sarah, Van Steenkiste, Christophe, Van Vlierberghe, Hans, Vandewynckel, Yves-Paul, Vandierendonck, Aster, Verhelst, Xavier   +12 more
core   +2 more sources

Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR‐T Cell Engineering

Advanced Science, EarlyView.
This study compares charge‑neutral and cationic lipidnanoparticles (LNPs) for ex vivo mRNA delivery to T cells, revealing distinctdependencies on medium composition and T cell activation. Where conventional LNPs benefit from ApoE‐dependent T cell targeting, cationic DOTAP‑modified LNPs mediate unspecific charge‑dependent transfection.
Laure Harinck, Stijn De Munter, Margo De Velder, Joline Ingels, Dominika Berdecka, Ine Lentacker, Winnok H. De Vos, Bart Vandekerckhove, Kevin Braeckmans, Koen Raemdonck   +9 more
wiley   +1 more source

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY

HemaSphere, 2022
R. Mina, F. Bonello, F. Fazio, R. Saccardi, V. Bongarzoni, F. Marchesi, G. Bertuglia, P. Curci, R. M. Lemoli, S. Ballanti, T. Dentamaro, G. Benevolo, A. Capra, R. Floris, P. Tosi, A. Olivieri, D. Rota-Scalabrini, C. Cangialosi, M. Cavo, P. Corradini, G. Milone, M. Boccadoro, A. Larocca   +22 more
doaj   +1 more source

Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation

Frontiers in Oncology
Background/purposeDespite advances in chronic lymphocytic leukemia treatment, effective therapies for cases with Richter’s transformation (RT) are urgently needed. This study aimed to investigate the use of chimeric antigen receptor (CAR)-T cell infusion
Shaomei Feng, Peihao Zheng, Haidi Liu, Meiling Sun, Yuelu Guo, Lixia Ma, Rui Liu, Zhonghua Fu, Fan Yang, Xiaoyan Ke, Kai Hu   +10 more
doaj   +1 more source

Increased plasma viscosity as a reason for inappropriate erythropoietin formation [PDF]

, 1993
The aim of this study was to examine whether altered plasma viscosity could contribute to the inappropriately low production rate of erythropoietin (EPO) observed in patients suffering from hypergammaglobulinemias associated with multiple myeloma or ...
Eckardt, Kai-Uwe, Götz, Karlheinz, Hamann, M., Kurtz, Armin, Ratcliffe, P. J., Reinhart, W. H., Singh, A., Zimmermann, A.   +7 more
core   +2 more sources

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)

HemaSphere, 2022
M. D’Agostino, S. Bringhen, R. Ria, F. Ciceri, A. P. Falcone, M. Michieli, M. Grasso, F. Pane, M. Quaresima, F. Cattel, M. Mirabile, F. Fioritoni, M. T. Petrucci, V. Cotugno, A. Capra, S. Pezzatti, M. L. Mosca Siez, M. Cantonetti, G. Margiotta Casaluci, P. Bertazzoni, R. Floris, M. Offidani, G. Pietrantuono, A. Evangelista, M. Boccadoro, A. Larocca   +25 more
doaj   +1 more source

Myelomatous Pleural Effusion [PDF]

Multiple myeloma (MM) is a common hematologic malignancy. Pleural effusion is a rare presenting feature of multiple myeloma which carries a poor prognosis.
شیردل, عباس, عطاران, داود, غیاثی, تقی, قبادی مراللو, حسن   +3 more
core  

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T, Ferguson, Ian D, Hann, Byron C, Lam, Christine, Lin, Yu-Hsiu T, Liu, Hui, Liu, Jun O, Mariano, Margarette C, Mitsiades, Constantine S, Murnane, Megan, Smith, Geoffrey A, Taunton, Jack, Wiita, Arun P, Wong, Sandy W   +13 more
core   +2 more sources